The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Sharvadze G.G.

National Research Center for Preventive Medicine, Ministry of Health of Russia, Moscow, Russia

Mamedov M.N.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

Mardanov B.U.

National Medical Research Center for Preventive Medicine, Ministry of Health of Russia, Moscow, Russia, 101990

Evaluation of the cardiac status in men with benign prostatic hyperplasia

Authors:

Sharvadze G.G., Mamedov M.N., Mardanov B.U.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2017;20(4): 26‑30

Read: 3492 times


To cite this article:

Sharvadze GG, Mamedov MN, Mardanov BU. Evaluation of the cardiac status in men with benign prostatic hyperplasia. Russian Journal of Preventive Medicine. 2017;20(4):26‑30. (In Russ.)
https://doi.org/10.17116/profmed201720426-30

Recommended articles:
Features of como­rbidity pathology in young people. Russian Journal of Preventive Medi­cine. 2024;(11):63-69
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Gastric cancer: inci­dence, risk factors, screening. Russian Journal of Preventive Medi­cine. 2024;(12):135-139
Risk factors asso­ciated with myopic macu­lopathy in acquired myopia. Russian Annals of Ophthalmology. 2024;(5):35-45
Comparison of models for prediction of spontaneous preterm birth. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):10-19
Features of primary and recu­rrent ischemic stroke in men aged 18—50 years. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):65-74

References:

  1. Boytsov SA, Chuchalin AG. Recommendations on prevention of non-infectious diseases. M. 2013;5-6. (In Russ.).
  2. Boytsov SA, Samorodskaya IV, Semenov VYu. Influence of medical and non-medical factors on the mortality of the population, economic factors. Problems of social hygiene and the history of medicine. 2016;6:335-339. (In Russ.).
  3. Kearney PM, Whelton M, Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
  4. World Health Organization, Health statistics and informatics. Causes of death. 2008; Summary tables. 2011.
  5. Sharvadze GG, Kurbatov DG, Poddubskaya EA, Mamedov MN. Androgen deficiency and cardiovascular diseases: topical issues of comorbidity in clinical practice. Rational Pharmacotherapy in Cardiology. 2010;6(4):532-538. (In Russ.).
  6. Burke AP, Farb A, Malcolm GT, et al. Coronary risk factors and plaque morfology in men with coronary death who died suddenly. N Engl J Med. 1997;336:1276-1281.
  7. Whitworth JA. World Health Organization (WHO) International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
  8. Joseph C, Presti Jr. Benign prostatic hyperplasia incidence and epidemiology. 2007.
  9. Grigoryan VA, Dymov AM. Drug therapy for patients with giperplasiei prostaty s ispolzovaniem α1-adrenaloblokatorov. RMZ. 2007;29:2237. (In Russ.).
  10. Lopatkin NA, Alyaev YuG, Kogan MI, et al. Efficacy and safety of doxazosin in the treatment of patients with benign prostatic hyperplasia. Urology. 2003;5:24-26. (In Russ.).
  11. Demir O, Akgul K, Akar Z. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;1:29-34.
  12. Shah MI, Butler M, Bramley T, et. al. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. Curr Med Res Opin. 2007;23(2):417-426.
  13. Barentsz JO, Richenberg J, et. al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22(4):746-757.
  14. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995;168:7-12.
  15. Michel MC, Heemann U, Schumacher H. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004;172:1390-1393.
  16. Tomita K, Mizoue T, Matsumoto T. Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers. Int J Urol. 2009;16:493-498 (discussion 498).
  17. Vertkin AL, Adonina EV, Galkin IV, Keshokov RKh. Clinical pathology and features of pharmacotherapy of cardiovascular diseases and benign prostatic hyperplasia. Therapist. 2008;7:63-67. (In Russ.).
  18. Korneev IA, Alekseeva TA, Kogan MI, Pushkar DYu. Urology. 2016;2 (Annex 2):70-75. (In Russ.).
  19. Gu D, et al., Inter ASIA Collaborative Group: prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365:1398-1405.
  20. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol. 2011;8:483-494.
  21. Ozden C, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51:199-206;discussion 204-206.
  22. McConnell JD, et al. Medical therapy of prostatic symptoms (MTOPS) esearch group: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
  23. De Nunzio C, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570.
  24. Burke JP, et al. Diabetes and benign prostatic hyperplasia progression in Olmsted county, Minnesota. Urology. 2006;67:22-25.
  25. Zhang X, et al. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int. 2014;93:214-219.
  26. Barendrecht MM, Koopmans RP, de la Rosette JJ, et al. Treatment for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int. 2005;95(4):19-28.
  27. Oelke M, Bachmann A, Descazeaud О, et al. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. 2013.
  28. Ozden C, Ozdal OL, Urgancioglu G. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51:199-203.
  29. Kalinchenko SYu, Tuzikov IA. Diseases of the prostate and metabolic syndrome: a new pathogenetic concept (review). Medical alphabet. Hospital. 2011;4:38-43. (In Russ.).
  30. Savenkov MP, Volkova AS, Kirienko AV, Ivanov SN, Ivanova SV. Urodinamic effects of β-blockers: the benefits of nebivolol. Rational pharmacotherapy. 2008;3:65-69. (In Russ.).
  31. Shen F, Dong LN, Zhang XY, et al. Inhibitory effect of losartan on prostatic hyperplasia in spontaneous hypertension rats and its pathophysiological mechanism. Zhonghua Nan Ke Xue. 2012;18(7):600-605.
  32. Zhao Y, Peng J, Zheng L, et al. Transforming growth factor beta1 mediates apoptotic activity of angiotensin II type I receptor blocker on prostate epithelium in vitro. Prostate. 2010;70(8):899-905.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.